# Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

> **NCT00459277** · PHASE3 · COMPLETED · sponsor: **Archimedes Development Ltd** · enrollment: 73 (actual)

## Conditions studied

- Cancer Pain

## Interventions

- **DRUG:** Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)

## Key facts

- **NCT ID:** NCT00459277
- **Lead sponsor:** Archimedes Development Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-08
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2012-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00459277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00459277, "Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00459277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*